Follicular Thyroid Carcinoma - Clinical and Diagnostic Findings in a 20-Year Follow Up Study

Badulescu, Claudiu; Piciu, Doina; Apostu, Dragoș; Badan, M

doi:10.4183/aeb.2020.170

Cited by 12 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As FTC is very rare, studies that directly compare children with adults do not exist. However, studies of adult patients with FTC show similar patterns of metastasis compared to children, as FTC rarely metastasize to the cervical lymph nodes, but more often hematogenous to bones and lungs ( 22 – 24 ).…”

Section: Discussionmentioning

confidence: 99%

Long-Term Oncological Outcomes of Papillary Thyroid Cancer and Follicular Thyroid Cancer in Children: A Nationwide Population-Based Study

et al. 2022

View full text Add to dashboard Cite

IntroductionPediatric thyroid carcinoma is a rare malignancy and data on long-term oncological outcomes are sparse. The aim of this study was to describe the long-term oncological outcomes of pediatric papillary thyroid carcinoma (PTC) and follicular thyroid carcinoma (FTC) in a national cohort, and to identify risk factors for recurrence.MethodsWe conducted a nationwide, retrospective cohort study, in which we combined two national databases. Patients aged <18 years, diagnosed with PTC or FTC in the Netherlands between 2000 and 2016, were included. pT-stage, pN-stage, multifocality and angioinvasion were included in a Cox-regression analysis for the identification of risk factors for recurrence.Results133 patients were included: 110 with PTC and 23 with FTC. Patients with PTC most often presented with pT2 tumors (24%) and pN1b (45%). During a median follow-up of 11.3 years, 21 patients with PTC developed a recurrence (19%). Nineteen recurrences were regional (91%) and 2 were pulmonary (9%). No risk factors for recurrence could be determined. One patient who developed pulmonary recurrence died two years later. Cause of death was not captured. Patients with FTC most often presented with pT2 tumors (57%). One patient presented with pN1b (4%). In 70%, no lymph nodes were collected. None of the patients with FTC developed a recurrence or died.ConclusionPediatric PTC and FTC are two distinct diseases. Recurrence in pediatric PTC is common, but in FTC it is not. Survival for both pediatric PTC and FTC is very good.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-Term Oncological Outcomes of Papillary Thyroid Cancer and Follicular Thyroid Cancer in Children: A Nationwide Population-Based Study

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The majority (86%) of FTC is diagnosed in women above the age of 40 years [ 5 , 77 ]. Less than 5% of FTC is heritable and related to syndromes such as FAP, Cowden’s disease, ataxia telangiectasia, and Li-Fraumeni syndrome [ 78 , 79 ]. Follicular carcinoma can develop from a pre-existing follicular adenoma (FA) [ 9 , 80 , 81 ].…”

Section: Diagnosis and Management Of Follicular Carcinomamentioning

confidence: 99%

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

et al. 2023

View full text Add to dashboard Cite

Follicular thyroid carcinoma (FTC) is the second most common cancer of the thyroid gland, accounting for up to 20% of all primary malignant tumors in iodine-replete areas. The diagnostic work-up, staging, risk stratification, management, and follow-up strategies in patients who have FTC are modeled after those of papillary thyroid carcinoma (PTC), even though FTC is more aggressive. FTC has a greater propensity for haematogenous metastasis than PTC. Furthermore, FTC is a phenotypically and genotypically heterogeneous disease. The diagnosis and identification of markers of an aggressive FTC depend on the expertise and thoroughness of pathologists during histopathological analysis. An untreated or metastatic FTC is likely to de-differentiate and become poorly differentiated or undifferentiated and resistant to standard treatment. While thyroid lobectomy is adequate for the treatment of selected patients who have low-risk FTC, it is not advisable for patients whose tumor is larger than 4 cm in diameter or has extensive extra-thyroidal extension. Lobectomy is also not adequate for tumors that have aggressive mutations. Although the prognosis for over 80% of PTC and FTC is good, nearly 20% of the tumors behave aggressively. The introduction of radiomics, pathomics, genomics, transcriptomics, metabolomics, and liquid biopsy have led to improvements in the understanding of tumorigenesis, progression, treatment response, and prognostication of thyroid cancer. The article reviews the challenges that are encountered during the diagnostic work-up, staging, risk stratification, management, and follow-up of patients who have FTC. How the application of multi-omics can strengthen decision-making during the management of follicular carcinoma is also discussed.

show abstract

“…Follicular thyroid carcinoma (FTC) is a malignant tumor of the thyroid follicular epithelium that easily invades the capsule and blood vessels [ 71 ]. FTC is the most common histological type of epithelial thyroid carcinoma after papillary thyroid carcinoma (PTC) [ 72 , 73 ] and accounts for 6-10% of all thyroid cancers [ 74 ].…”

Section: The Functions Of Trim2 In Cancersmentioning

confidence: 99%

Expression and Role of TRIM2 in Human Diseases

Xiao

Liu

et al. 2022

BioMed Research International

View full text Add to dashboard Cite

Tripartite motif (TRIM) protein family proteins contain more than 80 members in humans, and most of these proteins exhibit E3 ubiquitin ligase activity mediated through a RING finger domain. Their biological functions are very complex, and they perform diverse functions in cell evolution processes, such as intracellular signaling, development, apoptosis, protein quality control, innate immunity, autophagy, and carcinogenesis. Tripartite motif-containing protein 2 (TRIM2), a member of the TRIM superfamily, is an 81 kDa multidomain protein, also known as CMT2R or RNF86, located at 4q31.3. TRIM2 functions as an E3 ubiquitin ligase. Current studies have shown that TRIM2 can play roles in neuroprotection, neuronal rapid ischemic tolerance, antiviral responses, neurological diseases, etc. Moreover, based on some studies in tumors, TRIM2 regulates tumor proliferation, migration, invasion, apoptosis, and drug resistance through different mechanisms and plays a critical role in tumor occurrence and development. This review is aimed at providing a systematic and comprehensive summary of research on TRIM2 and at exploring the potential role of TRIM2 as a biomarker and therapeutic target in many kinds of human diseases.

show abstract

Follicular Thyroid Carcinoma - Clinical and Diagnostic Findings in a 20-Year Follow Up Study

Cited by 12 publications

References 19 publications

Long-Term Oncological Outcomes of Papillary Thyroid Cancer and Follicular Thyroid Cancer in Children: A Nationwide Population-Based Study

Long-Term Oncological Outcomes of Papillary Thyroid Cancer and Follicular Thyroid Cancer in Children: A Nationwide Population-Based Study

Multi-Omics and Management of Follicular Carcinoma of the Thyroid

Expression and Role of TRIM2 in Human Diseases

Contact Info

Product

Resources

About